Strategic Acquisition MedAlliance was acquired by Cordis for up to 1.135 billion including regulatory and commercial milestone potential, indicating strong validation and a future sales channel through Cordis' global footprint.

Global Expansion Headquartered in Switzerland with offices across Germany, Singapore, UK, and USA, presenting multiple regional entry points and collaboration opportunities for distribution and clinical adoption in diverse markets.

Innovative DEB Portfolio SELUTION SLR offers sustained sirolimus release via MicroReservoirs and CAT coating technology, enabling differentiation in both coronary and peripheral arterial disease segments and potential cross-sell into related patient populations.

Clinical Momentum Ongoing high-profile studies and rapid enrollment milestones (over 1,660 patients in SELUTION DeNovo, first patient in LOVE-DEB study) create opportunities for investigator-sponsored trials, key opinion leader engagement, and data-driven selling points.

Regulatory and Market Access Early FDA Breakthrough Designation history and CE marks demonstrate a track record of regulatory success, suggesting easier pathways for new indications and smoother payer discussions to accelerate market access.